<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807309</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000271</org_study_id>
    <nct_id>NCT04807309</nct_id>
  </id_info>
  <brief_title>PRETELL: PREvention of TELomere-related Complications After Lung Transplant</brief_title>
  <acronym>PRETELL</acronym>
  <official_title>PRETELL: PREvention of TELomere-related Complications After Lung Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Danzol in lung transplant recipients with short&#xD;
      telomeres.&#xD;
&#xD;
      Subjects with short telomeres recipient of lung transplant, will be randomized in the first&#xD;
      month post-transplant to either placebo or Danazol (200mg bid) in a 2:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind 2:1 ratio</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Similar tablets will be generated.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>48 weeks</time_frame>
    <description>The incidence, severity, outcome, and relationship to study treatment of adverse events and serious adverse events.&#xD;
Change from baseline in clinical laboratory test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of WBC &lt;2000/µl</measure>
    <time_frame>48 weeks</time_frame>
    <description>-Occurrence of WBC &lt;2000/µl at any time during study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of events where WBC &lt; 2000/µl</measure>
    <time_frame>48 weeks</time_frame>
    <description>- Evaluating cumulative number of events where WBC &lt; 2000/µl</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Telomere length</measure>
    <time_frame>48 weeks</time_frame>
    <description>-Measure change in lymphocyte telomere length at end of study drug administration compared to screening</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Short Telomere Length</condition>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparison</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Danazol Pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Danazol 200mg orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol Pill</intervention_name>
    <description>Danazol 200 mg orally twice a day</description>
    <arm_group_label>Danazol Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than 18&#xD;
&#xD;
          2. Ability to give informed consent&#xD;
&#xD;
          3. Recipient of lung transplantation&#xD;
&#xD;
          4. Short telomeres assessed either pre-transplant or post-transplant with FLOW-FISH as&#xD;
             lymphocyte telomere length &lt;10th percentile predicted for age&#xD;
&#xD;
          5. Clinically stable one month after lung transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients on androgen hormones to include testosterone or high dose estrogen (estradiol&#xD;
             0.5 mg/day or greater) during 12 months prior to enrollment&#xD;
&#xD;
          2. Patients with active thrombosis or thromboembolic disease and history of such events&#xD;
             unless thrombosis is line related.&#xD;
&#xD;
          3. Undiagnosed abnormal genital bleeding, porphyria, androgen-dependent tumor, or&#xD;
             prostatic hypertrophy&#xD;
&#xD;
          4. Patients with active hepatitis B or C&#xD;
&#xD;
          5. Patients who have received a bone marrow transplant&#xD;
&#xD;
          6. Clinically unstable after lung transplantation&#xD;
&#xD;
          7. Current pregnancy, or unwillingness to take be on two forms of contraceptives&#xD;
             including a barrier method of birth control or practice abstinence to refrain from&#xD;
             pregnancy if of childbearing potential during the course of the study&#xD;
&#xD;
          8. Lactating women, due to the potentially harmful effects on the nursing child&#xD;
&#xD;
          9. Patients with abnormal liver function AST, ALT &gt;3 times normal&#xD;
&#xD;
         10. Subjects with a history of benign intracranial hypertension&#xD;
&#xD;
         11. Subjects with a history of liver disease not limited to alcoholic hepatitis/cirrhosis,&#xD;
             non-alcoholic steatohepatitis (NASH), autoimmune hepatitis (AIH), primary biliary&#xD;
             cirrhosis (PBC), and/or history of hepatic adenoma.&#xD;
&#xD;
         12. Subjects with poorly controlled or uncontrolled Type I or II diabetes mellitus&#xD;
&#xD;
         13. Significant renal abnormalities GFR&lt; 40 ml/min/m2&#xD;
&#xD;
         14. Significant cardiac dysfunction with ejection fraction less than 50%&#xD;
&#xD;
         15. Moribund status such as death is expected in the coming year&#xD;
&#xD;
         16. Currently taking carbamazepine, pimozide or lomitapide&#xD;
&#xD;
         17. Inability to understand the investigational nature of the study or to give informed&#xD;
             consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Souheil El-Chemaly, MD, MPH</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>Danazol</keyword>
  <keyword>Short telomere</keyword>
  <keyword>Lung transplant</keyword>
  <keyword>Prevention</keyword>
  <keyword>Leukopenia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

